Table 1 Study population demographics, overall treatment course with daily oral prednisone, and follow-up modalities
Patient no. | Sex | Age | Pathological evidence of extracardiac sarcoidosis (Y/N) | Daily corticosteroid dose and tapering protocol | Initial evaluation | 3-month visit evaluation | 6-month visit evaluation | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Initial dose | Dose at 3-month visit | Dose at 6-month visit | Dose modification at 9-month visit | Pulmonary function test | Echocardiography | Pulmonary function test | Echocardiography | PET/CT | Pulmonary function test | Echocardiography | PET/CT | ||||
1 | M | 50 | Y | 40 mg x 2 weeks, tapered to 20 mg | 20 mg | 20 mg | No change | Y | Y | Y | Y | Y | Y | N | Y |
2 | F | 49 | Y | 40 mg x 2 weeks, tapered to 20 mg | 20 mg | 7.5 mg | No change | Y | Y | N | N | Y | N | Y | Y |
3 | M | 35 | Y | 40 mg | 20 mg | 0 mg | No change | Y | Y | Y | Y | Y | N | Y | Y |
4 | M | 61 | Y | 20 mg x 4 weeks, tapered to 10 mg | 15 mg | 5 mg | No change | Y | Y | Y | N | Y | Y | N | Y |
5 | M | 57 | N | 40 mg x 2 weeks, tapered to 20 mg | 20 mg | 25 mg | No change | Y | Y | Y | Y | Y | Y | N | Y |
6 | M | 45 | N | 40 mg x 2 weeks, tapered to 20 mg | 10 mg | 10 mg | No change | Y | N | Y | N | N | N | Y | N |
7 | M | 77 | Y | 20 mg | 0 mg | 0 mg | No change | Y | N | N | N | N | Y | N | N |
8 | M | 38 | N | 40 mg x 2 weeks, tapered to 20 mg | 10 mg | 30mg x 4 weeks, tapered to 20 mg | Increased to 40 mg | Y | N | Y | Y | Y | Y | Y | Y |
9 | F | 63 | Y | 60 mg | 20 mg | 5 mg | No change | N | N | N | N | Y | N | N | Y |
10 | M | 48 | Y | 60 mg | 20 mg | 10 mg | No change | Y | Y | N | N | N | N | Y | Y |
11 | M | 49 | Y | 40 mg x 4 weeks, tapered to 25 mg | 20 mg | 10 mg | Decreased to 5 mg | Y | N | Y | N | Y | Y | N | Y |
12 | M | 61 | Y | 40 mg x 2 weeks, tapered to 20 mg | 40 mg x 4 weeks, tapered to 30 mg | 15 mg | No change | Y | N | N | N | Y | Y | N | N |
13 | F | 46 | N | 30 mg x 4 weeks, tapered to 20 mg | 40 mg x 4 weeks, tapered to 25 mg | 15 mg | No change | Y | Y | Y | N | Y | N | N | N |
14 | F | 33 | Y | 40 mg x 4 weeks, tapered to 20 mg | 10 mg | 10 mg | No change | Y | Y | N | Y | Y | Y | N | N |
15 | M | 49 | N | 20 mg | 20 mg | 5 mg | Decreased to 2.5 mg | Y | N | Y | Y | Y | Y | N | Y |
16 | M | 44 | N | 40 mg x 2 weeks, tapered to 20 mg | 20 mg | 10 mg | No change | Y | Y | Y | N | N | Y | N | N |